Comorbidity defines asthmatic patients' risk of COVID-19 hospitalization: A global perspective - 04/01/23

Abstract |
Background |
The global epidemiology of asthma among patients with coronavirus disease 2019 (COVID-19) presents striking geographic differences, defining prevalence zones of high and low co-occurrence of asthma and COVID-19.
Objective |
We aimed to compare asthma prevalence among hospitalized patients with COVID-19 in major global hubs across the world by applying common inclusion criteria and definitions.
Methods |
We built a network of 6 academic hospitals in Stanford (Stanford University)/the United States; Frankfurt (Goethe University), Giessen (Justus Liebig University), and Marburg (Philipps University)/Germany; and Moscow (Clinical Hospital 52 in collaboration with Sechenov University)/Russia. We collected clinical and laboratory data for patients hospitalized due to COVID-19.
Results |
Asthmatic individuals were overrepresented among hospitalized patients with COVID-19 in Stanford and underrepresented in Moscow and Germany as compared with their prevalence among adults in the local community. Asthma prevalence was similar among patients hospitalized in an intensive care unit and patients hospitalized in other than an intensive care unit, which implied that the risk for development of severe COVID-19 was not higher among asthmatic patients. The numbers of males and comorbidities were higher among patients with COVID-19 in the Stanford cohort, and the most frequent comorbidities among these patients with asthma were other chronic inflammatory airway disorders such as chronic obstructive pulmonary disease.
Conclusion |
The observed disparity in COVID-19–associated risk among asthmatic patients across countries and continents is connected to the varying prevalence of underlying comorbidities, particularly chronic obstructive pulmonary disease.
El texto completo de este artículo está disponible en PDF.Key words : Chronic airway in inflammation prevalence, chronic obstructive pulmonary disease, COPD, public health, SARS-CoV-2
Abbreviations used : COPD, COVID-19, ICU, SARS-CoV-2, T2
Esquema
The last 2 authors contributed equally to this article. |
|
Supported by the Universities Giessen and Marburg Lung Center, German Center for Lung Research, University Hospital Giessen and Marburg research funding according to Article 2, Section Discussion of the Cooperation Agreement, and the Deutsche Forschungsgemeinschaft (German Research Foundation)-SFB 1021 (project identifier 197785619), KFO 309 (project identifier 284237345), and SK 317/1-1 (project identifier 428518790), and the Foundation for Pathobiochemistry and Molecular Diagnostics (to C.S.). |
|
Disclosure of potential conflict of interest: C. Skevaki reports consultancy and research funding from Hycor Biomedical, Bencard Allergie and Thermo Fisher Scientific, as well as research funding from Mead Johnson Nutrition. D. Fomina reports receiving honoraria from Novartis, Shire, Takeda, and Behring CSL. G. Rohde reports personal fees from AstraZeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer and Vertex for consultancy during advisory board meetings and personal fees from AstraZeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Solvay, Takeda, Novartis, Pfizer and Vertex for lectures, including service on speakers bureaus. R. S. Chinthrajah reports receiving grant support from the Consortium for Food Allergy Research, National Institute of Allergy and Infectious Diseases (NIAID), Food Allergy Research and Education (FARE), Aimmune, DBV Technologies, Astellas, Novartis, Regeneron, and AstraZeneca and serving as an advisory board member for Alladapt Immunotherapeutics, Novartis, Sanofi, Allergenis, Intrommune Therapeutics, and Genentech. K. C. Nadeau reports receiving research funding from the NIAID; National Heart, Lung, and Blood Institute; National Institute of Environmental Health Sciences; and FARE. In addition, K. C. Nadeau reports being the director of the World Allergy Organization; serving as an adviser to Cour Pharma; being a cofounder of Before Brands, Alladapt, Latitude, and Ig-Genix; performing consultancy for Excellergy, Red Tree Ventures, and Phylaxis; being a member of the National Scientific Committee, Immune Tolerance Network, and National Institutes of Health clinical research centers; and holding the patents "Mixed Allergen Composition and Methods for Using the Same," "Granulocyte-Based Methods for Detecting and Monitoring Immune System Disorders," "Methods and Assays for Detecting and Quantifying Pure Subpopulations of White Blood Cells in Immune System Disorders," and "Methods of Isolating Allergen-Specific Antibodies from humans and Uses Thereof." The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 151 - N° 1
P. 110-117 - janvier 2023 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.